Trogenix has successfully raised $95 million in a Series A funding round, with significant backing from Eli Lilly, to advance its pioneering brain cancer therapy. The company’s innovative platform utilizes an adeno-associated virus (AAV) that carries two therapeutic payloads, employing a ‘Trojan horse’ strategy to effectively target cancer cells while minimizing damage to surrounding healthy tissue.
This funding milestone underscores the growing interest in novel cancer therapies that leverage advanced delivery mechanisms. As the oncology landscape becomes increasingly competitive, Trogenix’s approach could offer a differentiated solution in the treatment of brain tumors, which remain among the most challenging cancers to treat. The partnership with Eli Lilly not only provides financial support but also strategic insights from a leading player in the pharmaceutical industry, potentially accelerating Trogenix’s path to clinical trials and market entry.
Use the database as your supply chain compass →
